Effects of the PPAR-gamma Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Diabetic and Hypertensive Subjects.

Trial Profile

Effects of the PPAR-gamma Agonist Pioglitazone on Renal and Hormonal Responses to Salt in Diabetic and Hypertensive Subjects.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2011

At a glance

  • Drugs Pioglitazone (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 13 Jul 2011 Results published in the Journal of Clinical Endocrinology and Metabolism.
    • 23 Apr 2010 Results have been published (Diabetologia: 23 Apr 2010).
    • 09 Apr 2010 Additional lead trial centre (University of Lausanne Hospitals) added as reproted by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top